Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Salix Pharmaceuticals (SLXP)
Q3 2012 Earnings Call
November 07, 2012 5:00 pm ET
G. Michael Freeman - Associate Vice President of Investor Relations & Corporate Communications
Adam C. Derbyshire - Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Finance & Administration
Carolyn J. Logan - Chief Executive Officer, President, Director and Member of Pricing Committee
William P. Forbes - Chief Development Officer and Executive Vice President of Research & Development
Annabel Samimy - Stifel, Nicolaus & Co., Inc., Research Division
Michael Faerm - Crédit Suisse AG, Research Division
Gary Nachman - Susquehanna Financial Group, LLLP, Research Division
David G. Buck - The Buckingham Research Group Incorporated
David Amsellem - Piper Jaffray Companies, Research Division
Gregory B. Gilbert - BofA Merrill Lynch, Research Division
Ami Fadia - UBS Investment Bank, Research Division
Irina Rivkind - Cantor Fitzgerald & Co., Research Division
Michael Kallai Tong - Wells Fargo Securities, LLC, Research Division
Jason M. Gerberry - Leerink Swann LLC, Research Division
Tim Lugo - William Blair & Company L.L.C., Research Division
Previous Statements by SLXP
» Salix Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
» Salix Pharmaceuticals Ltd Q3 2009 Earnings Call Transcript
» Salix Pharmaceuticals, Ltd. Q4 2008 Earnings Call Transcript
G. Michael Freeman
Good afternoon. Thank you for joining us today. I am Mike Freeman, Associate Vice President of Investor Relations and Corporate Communications for Salix Pharmaceuticals. With me today are Carolyn Logan, President and Chief Executive Officer; Adam Derbyshire, Executive Vice President and Chief Financial Officer; and Bill Forbes, Executive Vice President, Medical and Research and Development, and Chief Development Officer.
Adam will begin the presentation with a review of the financial results for the third quarter of 2012. Carolyn then will review operations to complete the formal segment of today’s call. At the conclusion of each comments, management will respond to appropriate questions.
Various remarks that management might make during this conference call about future expectations, plans and prospects for the company constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our press releases and SEC filings, including our Form 10-K for 2011. Specifically, the information in this conference call related to projections, development plans and other forward-looking statements is subject to this Safe Harbor.
I now will turn the call over to Adam.
Adam C. Derbyshire
Thank you, Mike. Total product revenue was $185.1 million for the third quarter of 2012, a 27% increase compared to $146.2 million for the third quarter of 2011. Total product revenue for the first 9 months of 2012 was $537.3 million, a 39% increase compared to $385.3 million for the first 9 months of 2011.
XIFAXAN revenue for the third quarter of 2012 was $137.9 million, a 43% increase compared to $96.7 million for the third quarter of 2011.
XIFAXAN revenue for the first 9 months of 2012 was $367.5 million, a 39% increase compared to $264.4 million for the first 9 months of 2011. APRISO revenue for the third quarter of 2012 was $19.7 million, a 31% increase compared to $15 million for the third quarter of 2011. The combined revenue contribution of our most recently introduced products, RELISTOR, SOLESTA and DEFLUX, totaled $12.1 million for the third quarter of 2012.
Total cost of products sold was $26.5 million for the third quarter of 2012 and $93.9 million for the first 9 months of 2012, compared to $24.1 million for the third quarter of 2011 and $67.9 million for the first 9 months of 2011.
Gross margin on total product revenue was 85.7% for the third quarter of 2012 compared to 83.5% for the third quarter of 2011, and 82.5% for the first 9 months of 2012 compared to 82.4% for the first 9 months of 2011.
Research and development expenses were $32.8 million for the third quarter of 2012 and $86.7 million for the first 9 months of 2012, compared to $24.8 million and $85.3 million, respectively, for the prior year periods.
The increase in research and development expenses for 2012 compared to 2011 is due primarily to increased expenses related to our Phase III retreatment study of rifaximin for irritable bowel syndrome with diarrhea.
Selling, general and administrative expenses were $61.5 million for the third quarter of 2012 compared to $41.4 million for the prior year period, and $187.3 million for the first 9 months of 2012 compared to $132.8 million for the prior year period.
The increase in selling, general and administrative expenses for 2012 compared to 2011 is due primarily to increased personnel costs related to our sales force expansion in 2012 and increased marketing expenses related to SOLESTA and XIFAXAN550 for hepatic encephalopathy.
The company reported GAAP net income of $16.5 million or $0.26 per share, fully diluted, for the third quarter of 2012, and $46.4 million or $0.73 per share, fully diluted, for the 9-month period ended September 30, 2012.
Net income on a non-GAAP basis, excluding the loss on extinguishment of debt and noncash adjustments related to the repurchase of a portion of our 2028 Notes in March of 2012, the intangible asset impairment charge and the change in acquisition-related contingent consideration that occurred in September 2012, the difference between income taxes paid and income taxes expensed and noncash depreciation, amortization, stock-based compensation and convertible debt interest expense was $59.7 million or $0.95 per share, fully diluted, for the 3-month period ended September 30, 2012, and $154.5 million or $2.43 per share, fully diluted, for the 9-month period ended September 30, 2012.
We believe these non-GAAP measures might provide investors additional relevant information, in part for purposes of historical comparison. In addition, we use these non-GAAP measures to analyze our performance in more detail and with better historical comparability. However, you should be aware that non-GAAP measures are not superior to nor a substitute for the comparable GAAP measures. We have provided in the press release issued earlier this afternoon a reconciliation of these measures to the most closely related GAAP measures.